M. Do

Discovery of IPN60090, a Clinical Stage Selective Glutaminase-1 (GLS-1) Inhibitor with Excellent Pharmacokinetic and Physicochemical Properties.

C. Rudin, Jason P. Burke, C. Bristow, 2020, Journal of medicinal chemistry.

Preclinical Characteristics of the Hepatitis C Virus NS3/4A Protease Inhibitor ITMN-191 (R7227)

Dylan P. Hartley, Jin Hong, Lin Pan, 2008, Antimicrobial Agents and Chemotherapy.

An inhibitor of oxidative phosphorylation exploits cancer vulnerability

M. Protopopova, R. DePinho, M. Konopleva, 2018, Nature Medicine.

Discovery of 7-tetrahydropyran-2-yl chromans: β-site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitors that reduce amyloid β-protein (Aβ) in the central nervous system.

K. Scearce-Levie, M. Volgraf, G. Vigers, 2014, Journal of medicinal chemistry.

Abstract 312: The ATR inhibitor ART0380 shows preclinical efficacy in monotherapy or in combination with gemcitabine, aPD1, PARP inhibitors and topoisomerase 1 poisons

V. Grinkevich, E. Rajendra, M. Ranzani, 2023, Cancer Research.

Abstract PR01: IACS-010759 a novel inhibitor of oxidative phosphorylation advancing into first-in-human studies to exploit metabolic vulnerabilities

M. Protopopova, M. Konopleva, C. Bristow, 2017 .

Abstract A65: IACS-10759: A novel OXPHOS inhibitor that selectively kills tumors with metabolic vulnerabilities

Edward F. Chang, L. Chin, M. Protopopova, 2016 .

An inhibitor of oxidative phosphorylation exploits cancer vulnerability

M. Protopopova, R. DePinho, M. Konopleva, 2018, Nature Medicine.